Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353767 | 0.92 | PKM (0.66) | KMT2APOLBALDH1A1PKMMAPK1 | |
| SCHEMBL13045322 | 0.86 | KMT2A (0.76) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6295349 | 0.85 | MBTD1 (0.59) | KMT2ACYP3A4CYP2D6CYP2C19MBTD1 | |
| SCHEMBL9885409 | 0.84 | KMT2A (0.76) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6035036 | 0.84 | KMT2A (0.76) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9885366 | 0.84 | POLB (0.78) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6107281 | 0.84 | KMT2A (0.76) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3326014 | 0.84 | KMT2A (0.76) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12509429 | 0.82 | KMT2A (0.73) | KMT2APOLBCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12422700 | 0.81 | KMT2A (0.71) | KMT2APOLBCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | claimed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | claimed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | claimed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | claimed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | claimed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | disclosed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | disclosed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | disclosed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| CN-1173170-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-02-11 | — | — | CN | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | ARSA, SMS, SULT1E1 | KMT2A 1249/4885POLB 1502/4885CYP3A4 49/4885 |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | KMT2A 4072/4885POLB 1268/4885CYP3A4 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.